9.88
-0.46 (-4.45%)
| Penutupan Terdahulu | 10.34 |
| Buka | 10.40 |
| Jumlah Dagangan | 540,506 |
| Purata Dagangan (3B) | 1,320,821 |
| Modal Pasaran | 537,669,440 |
| Harga / Jualan (P/S) | 195.11 |
| Harga / Buku (P/B) | 1.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Operasi (TTM) | -5,656.01% |
| EPS Cair (TTM) | -1.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.38% |
| Nisbah Semasa (MRQ) | 47.43 |
| Aliran Tunai Operasi (OCF TTM) | -82.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.18 M |
| Pulangan Atas Aset (ROA TTM) | -16.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Upstream Bio, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.50 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 14.84% |
| % Dimiliki oleh Institusi | 89.32% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Dec 2025 | 3,143,078 |
| Altshuler Shaham Ltd | 31 Dec 2025 | 1,341,540 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2025 | 1,329,544 |
| Omega Fund Management, Llc | 31 Dec 2025 | 1,326,293 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |